ClinicalTrials.gg
CompletedNCT02795780Updated Aug 24, 2020Results posted

Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05

A Phase 2 interventional study of Flortaucipir F18 and PET Scan in Alzheimer's Disease, sponsored by Avid Radiopharmaceuticals. Completed at 22 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-08-24.

Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 2, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
79
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.

Enrollment
11th of 22
79 · median 70
Started
2016
with 2 others
Phase 2
6 of 22
none open now
Registered
13th of 22
by date
Lead sponsor
15 of 22
Avid Radiopharmaceuticals

Among the 22 studies testing flortaucipir in Alzheimer Disease, this one is the 11th largest by enrollment, is one of 3 that started in 2016, is one of 6 in phase 2, and was the 13th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About flortaucipir

flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing flortaucipir in Alzheimer Disease, or all of them as a file.
02

Study summary

This study will evaluate longitudinal change of tau deposition as measured by flortaucipir F 18 uptake over time.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmatory cohort subjects who completed the 18F-AV-1451-A05 (NCT02016560) study

Exclusion criteria

Exclusion Criteria:

  • Current cardiovascular disease, abnormalities, risk factors for Torsades de Pointes (TdP), or are taking drugs known to cause
  • Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer
  • Females of who are not surgically sterile, not refraining from sexual activity or not using reliable methods of
  • Have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session
  • Have received or participated in a trial with medications in the past 30 days
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
79 participants (actual)

Study arms

  • Experimental
    Follow-up Flortaucipir PET Scan

    Drug: Flortaucipir F18 · Procedure: PET Scan

Interventions

  • 370 megabecquerel (MBq) IV single-dose

    Also known as: T807, 18F-AV-1451

  • ProcedurePET Scan

    positron emission tomography (PET) scan

06

What researchers measure

Primary outcomes

  1. Change in Tau Deposition Over Time by Diagnostic Group and Amyloid Status

    Change in flortaucipir standardized uptake value ratio (SUVr) over 18 months. For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain. A positive change in SUVr represents an increase in tau deposition in the brain. Change = 18 month SUVr - baseline SUVr obtained in Study A05.

    Time frame: 18 months

07

Results

Posted Aug 24, 2020

Participant flow

Enrolled between Aug 2016 and Aug 2017. The only subjects eligible were those who completed the Confirmatory Phase of Study A05 (NCT02016560).

Participant flow — Overall Study
MilestoneAD SubjectsMCI Subjects
Started2554
Completed2554
Not completed00

Outcome measures

PrimaryChange in Tau Deposition Over Time by Diagnostic Group and Amyloid Status

Change in flortaucipir standardized uptake value ratio (SUVr) over 18 months. For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain. A positive change in SUVr represents an increase in tau deposition in the brain. Change = 18 month SUVr - baseline SUVr obtained in Study A05.

Time frame:
18 months
Reported as:
Least squares mean · standardized uptake value ratio (SUVr)
Change in Tau Deposition Over Time by Diagnostic Group and Amyloid Status
standardized uptake value ratio (SUVr)AD Aβ+ SubjectsAD Aβ- SubjectsMCI Aβ+ SubjectsMCI Aβ- Subjects
Change in Tau Deposition Over Time by Diagnostic Group and Amyloid Status0.0205 ± 0.01871-0.0912 ± 0.036190.0352 ± 0.01185-0.0124 ± 0.01185
Statistical analysis
  • AD Aβ+ Subjects vs AD Aβ- Subjects · ANCOVA · p = 0.0166 (No adjustments for multiplicity. No a priori threshold defined.)Adjusted for baseline SUVr, age, and diagnosis group (AD/MCI)
  • MCI Aβ+ Subjects vs MCI Aβ- Subjects · ANCOVA · p = 0.0108 (No adjustments for multiplicity. No a priori threshold defined.)Adjusted for baseline SUVr, age, and diagnosis group (AD/MCI)

Adverse events

Collected over 48 hours after study drug administration. Non-serious events are listed at a 0.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MCI Subjects0/54 (0%)0/54 (0%)2/54 (3.7%)
AD Subjects0/25 (0%)0/25 (0%)0/25 (0%)
Most frequent other events
Most frequent other events
EventMCI SubjectsAD Subjects
injection site painGeneral disorders1/540/25
dizzinessNervous system disorders1/540/25
flushingVascular disorders1/540/25

Baseline characteristics

Age, Continuous
Age, Continuous(years)AD SubjectsMCI SubjectsTotal
Mean73.8 ± 10.6373.2 ± 9.173.4 ± 9.54
Sex: Female, Male
Sex: Female, Male(Participants)AD SubjectsMCI SubjectsTotal
Female92231
Male163248
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AD SubjectsMCI SubjectsTotal
Hispanic or Latino134
Not Hispanic or Latino245175
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AD SubjectsMCI SubjectsTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American033
White255176
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)AD SubjectsMCI SubjectsTotal
United States255479
MMSE
MMSE(units on a scale)AD SubjectsMCI SubjectsTotal
Mean23.7 ± 2.3925.9 ± 1.4825.2 ± 2.06
CDR-SB
CDR-SB(units on a scale)AD SubjectsMCI SubjectsTotal
Mean4.8 ± 1.532.6 ± 1.913.3 ± 2.05
Amyloid status
Amyloid status(Participants)AD SubjectsMCI SubjectsTotal
Amyloid positive192645
Amyloid Negative62834
08

Study locations

22 sites
  • Banner Alzheimer's Institute
    Phoenix, Arizona 85006, United States
  • Imaging Endpoints
    Scottsdale, Arizona 85258, United States
  • Mayo Clinic Arizona
    Scottsdale, Arizona 85259, United States
  • Banner Sun Health Research Institute
    Sun City, Arizona 85351, United States
  • Institute for Brain Aging and Dementia, UC Irvine
    Irvine, California 92697, United States
  • 21st Century Oncology
    Newport Beach, California 92663, United States
  • Alzheimer's Disease Center, UC Davis
    Sacramento, California 95817, United States
  • California Medical Clinic for Headache
    Santa Monica, California 90404, United States
  • Neuropsychiatric Research Center of Southwest Florida
    Fort Myers, Florida 33912, United States
  • Compass Research, LLC
    Orlando, Florida 32806, United States
  • Meridien Research
    Saint Petersburg, Florida 33709, United States
  • University of South Florida Health Byrd Alzheimer's Institute
    Tampa, Florida 33613, United States
  • Premiere Research Institute
    West Palm Beach, Florida 33407, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Boston University School of Medicine
    Boston, Massachusetts 02118, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Las Vegas Radiology
    Las Vegas, Nevada 89113, United States
  • New York University Center for Brain Health
    New York, New York 10016, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Butler Hospital
    Providence, Rhode Island 02906, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2016, a primary completion of Aug 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2020, 2 years 11 months after primary completion. A results delay was requested in Oct 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2016
First posted
Jun 10, 2016
Start
Aug 2016
Primary completionActual
Aug 28, 2017
CompletionActual
Aug 28, 2017
Results delay requested
Oct 23, 2018
Results first posted
Aug 24, 2020
Last update
Aug 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02795780
Responsible party
Sponsor
First posted
Jun 10, 2016
Start date
Aug 2016
Primary completion
Aug 28, 2017
Completion
Aug 28, 2017
Results posted
Aug 24, 2020
Last update
Aug 24, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flortaucipir

Start the discussion